-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the deepening of the concept of artificial intelligence, AI technology has gradually moved towards productization, industrialization and engineering, the research and development and application of artificial intelligence-related industries are also developing rapidly, and more and more industries are beginning to try the power of AI.
.
Among them, the pharmaceutical industry is undoubtedly one of the fields that has been very active in the attention and application of AI
.
With the help of AI, the pharmaceutical equipment industry may usher in a major upgrade (Source: Pharmaceutical Network) For the popularity of AI in the pharmaceutical industry, the industry generally believes that this is mainly because new drug research and development is a large project, which requires a long time, Due to the high energy consumption, high risk and long payback period, the current global cost of new drug research and development is getting higher and higher
.
Therefore, in order to shorten the research and development cycle, save the cost of compound screening and clinical trials, and improve the success rate of drug development and product quality, more and more pharmaceutical companies have begun to use AI technology to deploy new drug research and development, and even drug production
.
Looking at the world, at present, a large number of domestic and foreign companies such as Novartis, Pfizer, GSK, AstraZeneca, Sanofi, Fosun Pharma, Qihui Biological have been testing the water layout of AI research and development of new drugs, and they are in the AI pharmacy track.
.
Taking Fosun Pharma as an example, it has made frequent moves in AI this year
.
On January 11 this year, Fosun Pharma announced a "marriage" with Insilicon, an artificial intelligence technology company
.
Then on February 17, the two parties announced that they had nominated the preclinical candidate compound ISM004-1057D of the collaborative project for new tumor immunotherapy
.
It is worth noting that Insilicon recently announced that it has used its self-developed artificial intelligence platform to nominate preclinical candidate compounds targeting QPCTL for innovative tumor immunotherapy
.
In addition to Fosun Pharma, Pfizer announced in mid-January that it would expand its existing strategic cooperation with PostEra to establish an artificial intelligence laboratory (AI Lab) to jointly promote the development of new drugs
.
On January 7, Sanofi and Exscientia also jointly announced that the two parties have reached an advance payment of 100 million US dollars and a total of about 5.
2 billion US dollars of cooperation..
The parties will leverage Exscientia's end-to-end AI-driven platform utilizing actual patient samples to develop up to 15 novel small molecule drug candidates in oncology and immunology
.
Throughout the country and abroad, a large number of pharmaceutical companies are actively deploying in the field of AI pharmaceuticals
.
According to the current hot development in the field of AI pharmacy, in 2022, its development will continue to make great strides under the pursuit of capital
.
Affected by this, drug R&D innovation is expected to continue to accelerate, and patients will have more options for treatment in the future
.
In addition, it is worth noting that some people in the industry have proposed that as the application scope of AI becomes wider and wider, the pharmaceutical industry has entered the era of AI pharmacy, and the integration of AI and the pharmaceutical equipment industry will be further accelerated
.
It is reported that many pharmaceutical equipment companies have already begun to join the exploration of AI + pharmaceutical equipment, and have carried out active practice
.
For example, some compressor manufacturers have used full-digital traceability systems, smart sensors, visual inspection, and automatic monitoring systems to help pharmaceutical companies improve their production quality control systems, increase labor productivity by 30%, and further meet customer needs
.
There are also a large number of enterprises that are focusing their firepower to promote the "robots instead of manual" production model, using Internet technology, Internet of Things technology, automated logistics systems and other technologies to break the traditional process
.
The analysis believes that, from an overall perspective, AI has gradually become a new breakthrough in promoting the high-quality development of the pharmaceutical equipment industry, and it continues to have an impact on technological innovation, management, and systems
.
In this context, as AI continues to promote the technological transformation and optimization and upgrading of the pharmaceutical equipment industry, the industry expects that the future pharmaceutical equipment industry model and enterprise form may also undergo fundamental changes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, the pharmaceutical industry is undoubtedly one of the fields that has been very active in the attention and application of AI
.
With the help of AI, the pharmaceutical equipment industry may usher in a major upgrade (Source: Pharmaceutical Network) For the popularity of AI in the pharmaceutical industry, the industry generally believes that this is mainly because new drug research and development is a large project, which requires a long time, Due to the high energy consumption, high risk and long payback period, the current global cost of new drug research and development is getting higher and higher
.
Therefore, in order to shorten the research and development cycle, save the cost of compound screening and clinical trials, and improve the success rate of drug development and product quality, more and more pharmaceutical companies have begun to use AI technology to deploy new drug research and development, and even drug production
.
Looking at the world, at present, a large number of domestic and foreign companies such as Novartis, Pfizer, GSK, AstraZeneca, Sanofi, Fosun Pharma, Qihui Biological have been testing the water layout of AI research and development of new drugs, and they are in the AI pharmacy track.
.
Taking Fosun Pharma as an example, it has made frequent moves in AI this year
.
On January 11 this year, Fosun Pharma announced a "marriage" with Insilicon, an artificial intelligence technology company
.
Then on February 17, the two parties announced that they had nominated the preclinical candidate compound ISM004-1057D of the collaborative project for new tumor immunotherapy
.
It is worth noting that Insilicon recently announced that it has used its self-developed artificial intelligence platform to nominate preclinical candidate compounds targeting QPCTL for innovative tumor immunotherapy
.
In addition to Fosun Pharma, Pfizer announced in mid-January that it would expand its existing strategic cooperation with PostEra to establish an artificial intelligence laboratory (AI Lab) to jointly promote the development of new drugs
.
On January 7, Sanofi and Exscientia also jointly announced that the two parties have reached an advance payment of 100 million US dollars and a total of about 5.
2 billion US dollars of cooperation..
The parties will leverage Exscientia's end-to-end AI-driven platform utilizing actual patient samples to develop up to 15 novel small molecule drug candidates in oncology and immunology
.
Throughout the country and abroad, a large number of pharmaceutical companies are actively deploying in the field of AI pharmaceuticals
.
According to the current hot development in the field of AI pharmacy, in 2022, its development will continue to make great strides under the pursuit of capital
.
Affected by this, drug R&D innovation is expected to continue to accelerate, and patients will have more options for treatment in the future
.
In addition, it is worth noting that some people in the industry have proposed that as the application scope of AI becomes wider and wider, the pharmaceutical industry has entered the era of AI pharmacy, and the integration of AI and the pharmaceutical equipment industry will be further accelerated
.
It is reported that many pharmaceutical equipment companies have already begun to join the exploration of AI + pharmaceutical equipment, and have carried out active practice
.
For example, some compressor manufacturers have used full-digital traceability systems, smart sensors, visual inspection, and automatic monitoring systems to help pharmaceutical companies improve their production quality control systems, increase labor productivity by 30%, and further meet customer needs
.
There are also a large number of enterprises that are focusing their firepower to promote the "robots instead of manual" production model, using Internet technology, Internet of Things technology, automated logistics systems and other technologies to break the traditional process
.
The analysis believes that, from an overall perspective, AI has gradually become a new breakthrough in promoting the high-quality development of the pharmaceutical equipment industry, and it continues to have an impact on technological innovation, management, and systems
.
In this context, as AI continues to promote the technological transformation and optimization and upgrading of the pharmaceutical equipment industry, the industry expects that the future pharmaceutical equipment industry model and enterprise form may also undergo fundamental changes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
